Cargando…
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells
BACKGROUND: Epigenetic modifications play a critical role in the regulation of all DNA-based processes, such as transcription, repair, and replication. Inappropriate histone modifications can result in dysregulation of cell growth, leading to neoplastic transformation and cell death. Renal tumors ha...
Autores principales: | Park, Ki Cheong, Heo, Jun Hyeok, Jeon, Jeong Yong, Choi, Hye Ji, Jo, A Ra, Kim, Seung Won, Kwon, Ho Jeong, Hong, Sung Joon, Han, Kyung Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318161/ https://www.ncbi.nlm.nih.gov/pubmed/25613585 http://dx.doi.org/10.1186/s12885-014-1003-1 |
Ejemplares similares
-
Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer
por: Kim, Seok-Mo, et al.
Publicado: (2015) -
Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
por: Park, Ki Cheong, et al.
Publicado: (2017) -
Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models
por: Yun, Hyeok Jun, et al.
Publicado: (2021) -
Corrigendum to “Synergistic Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide and Sorafenib against Cancer Stem Cells, Anaplastic Thyroid Cancer” [Neoplasia 19 (2017) 145-153]
por: Park, Ki Cheong, et al.
Publicado: (2017) -
Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)